Latest Earnings Results: Q3 '26
Estimated EPS
$0.19
Reported EPS
$0.25
Surprise
+28.57%
Estimated Rev
$98.6M
Reported Rev
$99.3M
Surprise
+0.71%
• Reported GAAP EPS of $0.25 down -24.24% YoY • Reported revenue of $99.3M up 38.61% YoY • Harrow reaffirmed full-year 2026 revenue guidance of $350M to $365M and updated full-year 2026 Adjusted EBITDA guidance to more than $40M, including fourth-quarter Adjusted EBITDA of more than $33M.
Bullish Takeaway
Harrow's branded revenue and VEVYE prescriptions grew year over year, TYRVAYA added a complementary dry-eye brand and commercial personnel, and G-MELT's NDA submission is planned earlier than anticipated, with OPUVIZ's 2027 U.S. launch anticipated.
Bearish Takeaway
Harrow updated its Adjusted EBITDA outlook, citing first-half operating shortfall and added spending, reported operating cash use over nine months, and QUELL did not meet its prespecified non-inferiority endpoint.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $0.63 | -- | -- | N/A |
Q3 '26 | $0.19 | $0.25 | 28.57% | BEAT |
Q2 '26 | -$0.31 | -$0.46 | -50.82% | MISSED |
Q1 '26 | -$0.35 | -$0.74 | -109.19% | MISSED |
Q4 '25 | $0.37 | $0.17 | -53.78% | MISSED |